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Abstract
We investigated serotype 6A/6C invasive pneumococcal disease (IPD) incidence, genetic 
diversity, and carriage before and after 7-valent pneumococcal conjugate vaccine (PCV7) 
introduction in Alaska. IPD cases (1986–2009) were identified through population-based 
laboratory surveillance. Isolates were initially serotyped by conventional methods, and 6C isolates 
were differentiated from 6A by polymerase chain reaction. Among invasive and carriage isolates 
initially typed as 6A, 35% and 50% were identified as 6C, respectively. IPD rates caused by 
serotype 6A or 6C among children <5 years did not change from the pre- to post-PCV7 period (P 
= 0.71 and P = 0.09, respectively). Multilocus sequence typing of IPD isolates revealed 28 
sequence types. The proportion of serotype 6A carriage isolates decreased from 7.4% pre-PCV7 to 
1.8% (P < 0.001) during 2008–2009; the proportion of serotype 6C carriage isolates increased 
from 3.0% to 8.4% (P = 0.004) among children <5 years. Continued surveillance is warranted to 
monitor changes in serotype distribution and prevalence.
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1. Introduction
Streptococcus pneumoniae remains a leading cause of bacterial pneumonia, otitis media, 
sepsis, meningitis, and bacteremia worldwide, resulting in significant morbidity and 
mortality. The most important virulence factor of the pneumococcus is the polysaccharide 
capsule which surrounds the bacterium and protects it from phagocytosis by host immune 
cells. The polysaccharide capsule of S. pneumoniae is antigenically diverse and has formed 
the basis for serologic classification of pneumococci. Greater than 90 different serotypes 
have been described, including the recently discovered serotype 6C (Park et al., 2007a, 
2007b). This serotype is phenotypically indistinguishable from serotype 6A when using the 
Quellung reaction for serotyping but has a chemical structure distinct from 6A by virtue of 
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the change in the wciN gene region of the capsular locus encoding for galactosyl transferase 
(Park et al., 2007a).
One of the strategies used to reduce the incidence of invasive pneumococcal disease is 
vaccination directed against the pneumococcal polysaccharide capsule. In children <2 years 
of age, where the greatest burden of disease exists, recent efforts to develop effective 
pneumococcal vaccines have been concentrated on conjugate vaccines in which the capsular 
polysaccharides are covalently coupled to carrier proteins. The first such conjugate vaccine 
(PCV7), which was introduced into the universal immunization program in the United States 
in 2000, contains the 7 most common pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 
and 23F) causing invasive disease in infants and young children prior to its introduction in 
2000. This vaccine confers protection against serotype 6B, and most (Dagan et al., 1996, 
2002; Eskola et al., 2001) but not all (Mbelle et al., 1999) studies have found that PCV7 
provides cross-protection against serotype 6A. More recently, IPD data suggest that PCV7 
does not provide cross-protection against serotype 6C (Carvalho et al., 2009; Green et al., 
2011; Millar et al., 2010; Park et al., 2008b). The next-generation pneumococcal conjugate 
vaccine, PCV13, which contains the PCV7 serotypes plus serotypes 1, 3, 5, 6A, 7F, and 
19A, was introduced into the routine vaccination schedule for children in the USA in 2010.
In Alaska, pneumococcal disease rates have been among the highest reported in the world, 
particularly among Alaska Native children less than 2 years of age (Davidson et al., 1994). 
Studies in Alaska have also demonstrated pneumococcal carriage to be high among Alaska 
Native children (Hennessy et al., 2005; Park et al., 2008b). PCV7 was introduced into the 
routine childhood vaccination schedule in Alaska in 2001. Uptake of this vaccine was rapid 
with 92% and 67% of 19–35-month-old Alaska Native and non-native children, 
respectively, having received this vaccine by 2003 (Hennessy et al., 2002). Coverage of 
PCV7 has remained high (Park et al., 2008b; Singleton et al., 2007; Wenger et al., 2010), 
and since introduction, rates of IPD caused by serotypes present in the vaccine decreased 
rapidly, but IPD rates caused by nonvaccine serotypes subsequently increased, specifically 
in Alaska Native children less than 5 years of age (Singleton et al., 2007; Wenger et al., 
2010). In these studies, serotype 6A was not differentiated from serotype 6C. Here we 
describe the impact of the PCV7 introduction in Alaska (2001) on serotypes 6A and 6C by 
1) re-serotyping all invasive and carriage isolates previously characterized as serotype 6A, 
2) determining antimicrobial resistance among isolates, and 3) characterizing the genetic 
diversity of serotype 6A and serotype 6C invasive isolates using multilocus sequence typing 
(MLST).
2. Materials and methods
2.1. Invasive disease surveillance (1986–2009)
The Arctic Investigations Program (AIP) established a population-based statewide 
surveillance system to monitor invasive pneumococcal disease (IPD) in 1986. Isolates of S. 
pneumoniae are received at the AIP laboratory in Anchorage, AK, from 23 regional hospital 
laboratories processing sterile site specimens (blood and cerebrospinal, pleural, peritoneal, 
or joint fluid) in the state. From 1986 through 2009, 2815 isolates of invasive S. pneumoniae 
were submitted to AIP. Pneumococci were confirmed by colony morphology, susceptibility 
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to optochin (Difco, Detroit, MI, USA), and bile solubility. All isolates were serotyped by 
slide agglutination and confirmed by the Quellung reaction using group- and type-specific 
antisera (Staten Serum Institute, Copenhagen, Denmark).
2.2. Carriage study (2000–2004, 2008–2009)
Detailed methods of the carriage study conducted prior to 2008 have been described 
(Hammitt et al., 2006; Hennessy et al., 2002; Moore et al., 2004). In 2008 and 2009, we 
conducted community-wide surveys of pneumococcal nasopharyngeal colonization in 4 
rural villages during April and May that had been surveyed from 2000 to 2004. In addition, 
we conducted observational, cross-sectional carriage surveys at 3 Anchorage pediatric 
clinics during February and March. Laboratory methods for the carriage study were as 
previously described except for during 2008–2009 where STGG (skim milk, tryptone, 
glucose, and glycerine) was used as the transport media. These studies were approved by the 
Alaska Area and Centers for Disease Control and Prevention institutional review boards. 
Written informed consent was obtained from adult study participants for themselves and for 
their children in the rural arm of the study and from the parent or guardian of children 
enrolled in the Anchorage arm of the study.
2.3. Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MIC) were determined for each IPD isolate by 
microbroth dilution and for colonizing pneumococci by Etest (AB BIODISK, Piscataway, 
NJ, USA). Isolates with penicillin MICs of ≥2 and 0.12–1.0 μg/mL were considered to be 
resistant and intermediately resistant to penicillin, respectively (CLSI, 2007 guidelines). 
Multidrug-resistant isolates were defined as having intermediate or full resistance to 3 or 
more different classes of antibiotics.
2.4. Serotype 6C determination
Crude DNA extracts from all invasive pneumococcal isolates and carriage isolates 
previously reported as serotype 6A were prepared and subjected to a multiplex polymerase 
chain reaction (PCR) assay containing primer pairs specific for cpsA and serogroup 6, as 
previously described (Pai et al., 2006). Serotype 6C was differentiated from serotypes 6A 
and 6B by a third primer pair specific for the wciN gene (Carvalho et al., 2009).
2.5. MLST analysis
Multilocus sequence typing (MLST) was performed as previously described (Enright and 
Spratt, 1998), with modifications (Moore et al., 2008) on invasive serotype 6A and 6C 
isolates recovered from 1986 to 2009. The sequence types (ST) were determined by 
comparing the sequences with alleles downloaded from the pneumococcal MLST database 
(http://spneumoniae.mlst.net). Clonal complexes were assigned using the eBURST 
algorithm with the software available at the MLST website (http://www.mlst.net).
2.6. Statistical analysis
To compare rates of IPD, we used 1986–1993 and 1994–2000 as pre-PCV7 vaccine periods 
and 2001–2009 as the post-PCV7 period. To calculate incidence, population estimates were 
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obtained from the Alaska Department of Labor and Workforce Development website. We 
assessed changes in IPD incidence of serotype 6A and 6C by use of a trend test for Poisson 
rates. We assessed the proportion of carriage isolates that were serotype 6A and 6C among 
pneumococcal carriers using the Cochran–Armitage test for trend. We compared 
antimicrobial resistance and clonal complex distribution between 2 periods by use of the 
likelihood ratio chi-square test. All P values were exact when sample size necessitated. All 
statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC, USA) and 
StatXact 8.0 (Cytel Corporation, Cambridge, MA, USA).
3. Results
3.1. Incidence and distribution of IPD caused by serotype 6A and 6C isolates
From 1986 to 2009, 2815 invasive pneumococcal isolates were received at AIP. Of these, 72 
(2.6%) were conventionally serotyped as 6A. With the use of multiplexed PCR assay to 
differentiate serotype 6C from serotype 6A isolates, 35% (25/72) of isolates conventionally 
serotyped as 6A were identified as 6C. Overall rates of IPD caused by serotype 6A did not 
change significantly from the pre- (1986–1993, 0.25/100,000; 1994–2000, 0.35/100,000) to 
the post-PCV7 period (2001–2009, 0.35/100,000). Likewise, rates of IPD caused by 
serotype 6C showed no significant differences in the pre-PCV7 periods (0.16/100,000 and 
0.09/100,000) and post-PCV7 periods (0.24/100,000). IPD rates in children <5 years of age 
were 1.81 per 100,000 persons for serotype 6A versus 0.24 per 100,000 persons for serotype 
6C for all years of surveillance combined. When we stratified by race and age group, no 
statistically significant changes in rates of invasive disease caused by serotype 6A or 6C 
were noted over the study period and pre- to post-vaccine years. Prior to the introduction of 
PCV7, the majority of IPD cases in Alaska due to serogroup 6 were caused by serotype 6B 
(81%); since 2004, only 3 cases of serotype 6B were seen compared to 13 cases of serotype 
6A and 14 cases of serotype 6C (Fig. 1).
Among serotype 6A and 6C cases, 60% had a clinical diagnosis of pneumonia, 31% had 
bacteremia and there were a total of 3 cases of meningitis. We found no difference between 
serotype 6A and 6C IPD with regard to gender, clinical presentation, or the case fatality 
ratio, however, serotype 6A isolates were more likely to be from children <5 years of age 
(49% [23/27]) than serotype 6C isolates (12% [3/25], P = 0.001).
3.2. Antimicrobial susceptibility
Susceptibility results for the invasive pneumococcal isolates are shown in Fig. 2. Among 
serotype 6A isolates, 49% (23/47) were susceptible to all antibiotics tested. Of the 15 
penicillin-nonsusceptible 6A isolates, 13 showed intermediate resistance to penicillin. In 
addition, 34% (16/47) were trimethoprim–sulfamethoxazole (TMP-SMX) nonsusceptible, 
32% (15/47) were erythromycin resistant, and 8.5% (4/47) were multidrug resistant. Among 
the serotype 6C isolates, 64% (16/25) were susceptible to all antibiotics tested. Five isolates 
(20%) were nonsusceptible to penicillin, 24% (6/25) were erythromycin- and TMP-SMX 
resistant, and 16% (4/25) were multidrug resistant.
Prior to the introduction of PCV7 in 2001, 8% (2/26) of serotype 6A isolates were penicillin 
or erythromycin nonsusceptible. After the introduction of PCV7, the proportion of serotype 
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6A isolates nonsusceptible to penicillin or erythromycin increased to 62% (13/21) (P < 
0.01). For serotype 6C isolates, nonsusceptibility to penicillin increased from 0% (0/11) to 
36% (5/14) (P = 0.05) and nonsusceptibility to TMP-SMX increased from 0% (0/11) to 43% 
(6/14).
3.3. Genotypes
MLST of the 47 serotype 6A isolates yielded 21 sequence types (STs), including 8 new STs 
(Table 1). Comparison of these STs with those present in the MLST database for S. 
pneumoniae by eBURST analysis showed that 17 of these STs fell into 7 clonal complexes 
(CCs) based on a minimum similarity of 5 identical loci and 3 singletons (Table 1). While 
the CC distribution of serotype 6A isolates changed from the pre-PCV7 and the post-PCV7 
period, it was not significant. Prior to the introduction of PCV7 in Alaska, the majority 
(81%, 21/26) of serotype 6A isolates clustered into 4 CCs (395, 460, 473, and 690); of these, 
the majority were in CC460 (38.5%, 10/26) and CC473 (27%, 7/26). After the introduction 
of PCV7, serotype 6A isolates clustered into 4 CCs (395, 460, 473, and 2090), the majority 
of which were in CC473 (57%, 12/21).
MLST of 25 serotype 6C isolates yielded 8 STs, including 2 new STs (Table 1). eBURST 
analysis revealed that all 8 STs fell into 3 CCs (CC473, CC1379, and CC1390). Eighteen 
(72%) serotype 6C isolates were related to STs associated with serotype 6A and included 
ST473 (n = 2), ST1390 (n = 5), ST1379 (n = 8), ST1292 (n = 3), and ST4333 (n = 1). The 
distribution of STs among the serotype 6C isolates differed significantly after the 
introduction of PCV7 (P = 0.002; Table 1). Prior to the introduction of PCV7, the majority 
(73%, 8/11) of serotype 6C isolates fell into CC1390. After the introduction of PCV7, the 
majority (71%, 10/14) of serotype 6C isolates fell into CC1379.
When we examined whether there was clustering of clonal complexes by epidemiologic 
characteristics, restricting our analysis to clonal complexes or STs with a sample size of ≥10 
isolates, we found no association between clonal complex or STs and age, gender, case 
fatality ratio, or clinical syndromes. We did not find any clustering of individual clonal 
complexes or STs according to the village residence of cases either.
3.4. Trends in serotype 6A and 6C carriage
Over all years of the study, 38% of children (<5 years of age) in urban Anchorage were 
carriers of pneumococcus, compared to 58% of rural children (<5 years of age) and 33% of 
persons ≥5 years of age in rural Alaska. Among 4667 pneumococcal carriage isolates (from 
carriage studies performed in 2000–2004 and 2008–2009), 440 (9%) were serotyped as 6A; 
50% (222/440) of isolates conventionally serotyped as 6A were subsequently identified as 
6C. Over the 4 time periods (2000, 2001–2002–2003–2004, and 2008–2009), the proportion 
of 6A carriage isolates among children <5 years of age decreased from 7.4% to 1.8% (P < 
0.001; Table 2). No statistically significant changes in the proportion of 6A carriage isolates 
were noted among participants ≥5 years of age in rural Alaska. However, statistically 
significant increases in the proportion of serotype 6C carriage isolates were noted among all 
study participants in all the study years following the introduction of PCV7 (Table 2). Forty-
eight percent of serotype 6A (104/218) and 8% of serotype 6C (18/221) carriage isolates 
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were nonsusceptible to penicillin. For TMP-SMX, 47% (103/218) and 7% (16/221) of 
carriage isolates were nonsusceptible among serotypes 6A and 6C, respectively.
4. Discussion
Serotype 6C was first described in 2007 (Park et al., 2007a). Since then, there have been a 
number of reports detailing the prevalence, antimicrobial susceptibility patterns, and genetic 
diversity among serotype 6C isolates collected from both invasive disease and 
nasopharyngeal colonization studies (Campos et al., 2009; Carvalho et al., 2009; du Plessis 
et al., 2008; Green et al., 2011; Hermans et al., 2008; Jacobs et al., 2008, 2009; Nahm et al., 
2009; Nunes et al., 2009; Rolo et al., 2011a; Tocheva et al., 2010). In studies that looked at 
the prevalence of serotype 6C among invasive and carriage isolates, it was found that 
anywhere between 5% and 100% of isolates that originally typed as 6A were subsequently 
identified as serotype 6C (Campos et al., 2009; Carvalho et al., 2009; du Plessis et al., 2008; 
Hermans et al., 2008; Jacobs et al., 2009; Millar et al., 2010; Rolo et al., 2011a). This large 
range was primarily due to the fact that the proportion of serotype 6C isolates increased over 
time, while the proportion of serotype 6A isolates decreased. In Alaska, we have conducted 
statewide laboratory surveillance for IPD since 1986. Prior to the introduction of PCV7, the 
majority of IPD due to serogroup 6 was caused by serotype 6B with a small proportion 
caused by serotype 6A (Fig. 1). By 2002, the number of IPD cases caused by serotype 6B 
had decreased to levels not seen in the previous 16 years and continued to decrease until the 
last case in 2006. While others have reported significant increases in IPD caused by serotype 
6C since the introduction of PCV7 along with significant decreases in serotype 6A IPD in 
the post-vaccine years, this has not been the case in our population (Carvalho et al., 2009; 
Millar et al., 2010). While we did see an increase in the incidence of serotype 6C IPD (0.16 
to 0.24 cases per 100,000 population), it was not statistically significant. Over this same 
time period (1986–2009), the incidence of serotype 6A IPD remained stable at about 0.3 
cases per 100,000 population. It is important to mention that while we did not see a 
significant decline in the rate of IPD caused by serotype 6A among children <5 years of age 
in the post-PCV7 era (2001–2009), we have not seen a case of 6A disease in children since 
2006. Breakdown by age of patients and ethnicity did show that the incidence of serotype 
6A IPD decreased from 6.1 to 1.62 cases per 100,000 population in Alaska Native children 
<5 years of age; however, there was no significant increase in serotype 6C IPD. It is 
interesting to note that the first case of invasive serotype 6C disease in children <5 years of 
age was not seen in Alaska until 2004, and only 2 cases (11%) in total were detected through 
2009. This is in contrast to IPD caused by serotype 6A where 53% of disease was in 
children <5 years of age. These findings are similar to those reported by Millar et al. (2010) 
who found that only 4% of serotype 6C cases occurred among children <5 years of age, 
while >40% of serotype 6A cases were among children <2 years of age.
Both serotype 6A and 6C isolates exhibited decreased susceptibility to penicillin after the 
introduction of PCV7. Others have reported finding significantly greater proportions of 
penicillin-resistant isolates within serotype 6A than within serotype 6C (Carvalho et al., 
2009; Park et al., 2008a). In contrast, we found that 32% of serotype 6A and 18.5% of 
serotype 6C isolates were nonsusceptible to penicillin. All of the serotype 6C isolates with 
reduced susceptibility to penicillin were found in the years (2007–2009) after the 
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introduction of PCV7, and of those, 40% were fully resistant. In addition to decreased 
susceptibility to penicillin, we have also seen decreased susceptibility to erythromycin and 
TMP-SMX among our serotype 6A and 6C isolates since the introduction of PCV7. 
Multidrug resistance among serotype 6C isolates increased later in the PCV7 era which is 
similar to what has previously been reported by others (du Plessis et al., 2008; Jacobs et al., 
2008; Rolo et al., 2011a). This increase in resistance to penicillin and multiple other 
antibiotics among serotype 6C isolates warrants close monitoring as we move into the new 
era of higher valency conjugate vaccines.
Among our collection of 47 invasive serotype 6A isolates, 21 different STs were found over 
this 30-year surveillance period. Two major lineages accounted for 66% of these isolates 
(CC473 and CC460). Similar findings have been reported by Jacobs et al. (2009) who found 
that among their serotype 6A isolates, the majority were STs 473, 460, 395, and 376. In the 
Carvalho et al. (2009) study, 4 STs (1292, 473, 395, and 376) were observed with ST376, 
accounting for approximately 30% of serotype 6As, including the majority of isolates fully 
resistant to penicillin and the majority of erythromycin-resistant isolates. In this study, the 
majority of penicillin-nonsusceptible serotype 6A isolates were ST473, ST660, or ST376, 
and only 1 ST473 isolate was fully resistant to penicillin.
The presence of 8 STs found among only 27 serotype 6C isolates in this study are consistent 
with other studies that have described a high degree of genetic diversity among this serotype 
(Campos et al., 2009; Carvalho et al., 2009; Green et al., 2011; Jacobs et al., 2009; Nunes et 
al., 2009; Rolo et al., 2011b). Of the 8 STs of serotype 6C isolates reported in this study, 4 
(1390, 1379, 473, and 1292) have been previously associated with serotype 6A. While 
ST2899 and ST4285 found in this study are associated solely with serotype 6C, they are 
double- and triple-locus variants, respectively, of ST1390. Other studies have reported 
similar findings (Carvalho et al., 2009; Green et al., 2011; Jacobs et al., 2009). Among the 
serotype 6C isolates analyzed by Jacobs et al. (2009), 9 MLST clusters were identified. Five 
of these clusters were related to clonal complexes associated with serotype 6A (473, 1379, 
490, 690, and 1390). Carvalho et al. (2009) reported that more than a third of the serotype 
6C isolates they analyzed were sequence types associated primarily with serotype 6A 
isolates. In the study by Green et al. (2011), 50% of the serotype 6C isolates analyzed were 
STs previously associated with serotype 6A. It is interesting to note that among the serotype 
6A and 6C isolates analyzed in this study, only isolates of ST473 were found within both 
serotypes and that ST1390 and ST1379, which are frequently found among serotype 6A 
isolates, were found exclusively among 6C isolates.
We have previously described the impact of PCV7 on nasopharyngeal carriage of 
pneumococci in community settings in the pre-PCV era (1998–2000) and the early PCV era 
(2001–2004) (Hammitt et al., 2006; Hennessy et al., 2005; Moore et al., 2004; Park et al. 
2008b; Singleton et al., 2007). In these reports, we described a rapid and significant decrease 
in carriage of vaccine types followed by a significant increase in carriage of nonvaccine 
types across all age groups; however, carriage of serotypes 6A and 6C was unaffected 
during this time period. While our data on the epidemiology of IPD due to serotypes 6A and 
6C showed little evidence of cross protection from PCV7, data from carriage studies 
performed in 2008–2009 showed a significant decrease in the proportion of serotype 6A 
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isolates carried by children <5 years of age. It is important to note that the decline in 
carriage of serotype 6A was delayed and not observed in the 3 years following PCV7 
introduction which is similar to what was observed for serotype 6A IPD. We also noted 
significant increases in the proportion of serotype 6C isolates carried among all study 
participants, regardless of age.
Our findings on disease rates are limited by the small population size leading to small 
numbers of cases. The small number of IPD cases of individual serotypes 6A and 6C limits 
our power to detect trends over time in these 2 serotypes. Therefore, long-term surveillance 
is important to confirm the trends we report here. Samples sizes of individual clonal 
complexes of 6A and 6C IPD limited our ability to test for epidemiologic differences 
between them.
In summary, serotype 6C isolates have been circulating in Alaska since we began IPD 
surveillance in 1986. While others have reported the near disappearance of serotype 6A IPD 
in the post-PCV7 era presumably due to the cross-protection provided by serotype 6B, we 
did not see a similar decline in serotype 6A IPD, particularly among children <5 years of 
age, for several years after PCV7 introduction. However, we did observe an increase in the 
rates of serotype 6C IPD. Among older children and adults, we observed an increase in 
serotype 6A IPD but no change in the incidence of serotype 6C IPD. The prevalence and 
distribution of pneumococcal serotypes has changed considerably since the introduction of 
PCV7. With the introduction of PCV13 into the routine childhood vaccination schedule 
statewide in 2010, we expect to see further declines in serotype 6A IPD and perhaps 
declines in serotype 6C IPD as a result of cross-protecting antibodies to the 6A antigen 
(Cooper et al., 2011). Continued surveillance for IPD will help us better assess the impact of 
this new vaccine.
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Distribution of invasive pneumococcal serotype 6A, 6B, and 6C isolates in Alaska over time 
(1986–2009), all ages.
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Antimicrobial resistance (% nonsusceptible) among invasive S. pneumoniae serotype 6A 
and 6C isolates from 1986 to 2009 in Alaska.
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